News Column

Findings from Department of Immunology in the Area of Thrombotic Microangiopathies Described (Spectrum of Complement-Mediated Thrombotic...

July 23, 2014



Findings from Department of Immunology in the Area of Thrombotic Microangiopathies Described (Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Blood Platelet Disorders. According to news reporting originating in Paris, France, by NewsRx journalists, research stated, "Thrombotic microangiopathy (TMA) is a rare but severe disorder characterized by endothelial cell activation and thrombus formation. It manifests with the triad of hemolytic anemia, thrombocytopenia, and organ failure."

The news reporters obtained a quote from the research from the Department of Immunology, "Prompt diagnosis and treatment initiation are crucial for long-term outcome. TMA often manifests subsequent to infectious events, of which (enterohemorrhagic) Escherichia coli is the most frequently reported. TMA also occurs on the background of genetic/autoimmune defects in the complement system (atypical hemolytic uremic syndrome [aHUS]) and underlying conditions, such as pregnancy, transplantation, drugs, other glomerulopathies, vasculitides, or metabolic defects. Complement activation or defects in its regulation have now been described in an increasing number of acquired diseases with TMA. Coinciding with this expanding spectrum of complement-mediated diseases, the question arises which patients might benefit from a complement-targeted therapy. Success of therapy depends on the individual contribution of complement activation in disease pathogenesis. The advent of eculizumab, a monoclonal antibody that blocks terminal complement activation, has markedly improved outcome and quality of life in patients with aHUS. This review discusses the contribution of complement and highlights its complex interaction with inflammation, coagulation, and the endothelium."

According to the news reporters, the research concluded: "Treatment experiences focusing on eculizumab therapy are discussed in detail across the emerging spectrum of complement-mediated thrombotic microangiopathies."

For more information on this research see: Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Seminars in Thrombosis and Hemostasis, 2014;40(4):444-464. Seminars in Thrombosis and Hemostasis can be contacted at: Thieme Medical Publ Inc, 333 Seventh Ave, New York, NY 10001, USA. (Thieme - www.thieme.com)

Our news correspondents report that additional information may be obtained by contacting M. Riedl, Hopital Europeen Georges Pompidou, AP HP, Dept. of Immunol, Paris, France. Additional authors for this research include F. Fakhouri, M. Le Quintrec, D.G. Noone, T.C. Jungraithmayr, V. Fremeaux-Bacchi and C. Licht (see also Blood Platelet Disorders).

Keywords for this news article include: Paris, France, Europe, Therapy, Hemolytic, Thrombocytopenia, Hematologic Diseases, Blood Platelet Disorders, Hemic and Lymphatic Diseases, Thrombotic Microangiopathies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters